Last reviewed · How we verify
Fentanyl transdermal therapeutic system
At a glance
| Generic name | Fentanyl transdermal therapeutic system |
|---|---|
| Sponsor | Johnson & Johnson Taiwan Ltd |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants (PHASE1)
- Bioequivalence Study of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Participants (PHASE1)
- MAST Trial: Multi-modal Analgesic Strategies in Trauma (PHASE4)
- Traumatologic Acute Pain Management With Fentanyl Transdermal Therapeutic System (TTS) (PHASE3)
- Fentanyl Patch Pharmacokinetics in Healthy Adults (PHASE4)
- Efficacy of Transdermal Fentanyl Patches in Relief of Acute Postoperative Pain After Mastectomy (PHASE4)
- Transdermal Fentanyl and Melatonin Patches for Postoperative Pain Relief
- An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer Pain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: